Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free XRN Stock Alerts

Global Medical REIT (XRN) Financials

Global Medical REIT logo
$35.93 +0.12 (+0.33%)
Closing price 06/5/2026 03:59 PM Eastern
Extended Trading
$35.92 0.00 (-0.01%)
As of 06/5/2026 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Global Medical REIT

Annual Income Statements for Global Medical REIT

This table shows Global Medical REIT's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 13 15 0.81
Consolidated Net Income / (Loss)		 20 22 6.69
Net Income / (Loss) Continuing Operations		 13 7.04 4.20
Total Pre-Tax Income 		13 7.04 4.20
Total Revenue		 112 110 110
Net Interest Income / (Expense)		 -25 -31 -29
Total Interest Income		 0.00 0.00 0.00
Total Interest Expense		 25 31 29
Long-Term Debt Interest Expense		 25 31 29
Total Non-Interest Income		 137 141 139
Other Service Charges		 0.12 0.12 0.37
Other Non-Interest Income		 137 141 138
Total Non-Interest Expense		 99 103 106
Other Operating Expenses		 42 45 50
Depreciation Expense		 40 41 40
Amortization Expense		 17 17 15
Restructuring Charge		 0.35 0.04 0.16
Other Gains / (Losses), net		 0.00 -0.87 -1.72
Net Income / (Loss) Discontinued Operations		 6.75 16 4.21
Preferred Stock Dividends Declared		 5.82 5.82 5.82
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.85 1.12 0.06
Basic Earnings per Share		 $0.20 $0.23 $0.01
Weighted Average Basic Shares Outstanding		 65.46M 65.55M 65.94M
Diluted Earnings per Share		 $0.20 $0.23 $0.01
Weighted Average Diluted Shares Outstanding		 65.46M 65.55M 65.94M
Weighted Average Basic & Diluted Shares Outstanding		 65.53M 65.57M 66.87M
Cash Dividends to Common per Share		 $0.84 $0.84 $0.84

Quarterly Income Statements for Global Medical REIT

This table shows Global Medical REIT's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 8.06 0.37 0.67 12 3.14 -0.84 0.79 -3.15 1.79 1.37
Consolidated Net Income / (Loss)		 10 1.85 2.17 14 4.83 0.55 2.31 -1.95 3.39 2.94
Net Income / (Loss) Continuing Operations		 3.28 1.85 1.69 1.39 2.54 1.42 2.31 1.43 1.57 -1.11
Total Pre-Tax Income 		3.28 1.85 1.69 1.39 2.54 1.42 2.31 1.43 1.57 -1.11
Total Revenue		 28 28 28 28 28 26 28 27 27 28
Net Interest Income / (Expense)		 -6.96 -8.07 -8.27 -8.47 -7.17 -6.98 -6.89 -6.99 -7.24 -7.57
Total Interest Expense		 6.96 8.07 8.27 8.47 7.17 6.98 6.89 6.99 7.24 7.57
Long-Term Debt Interest Expense		 6.96 8.07 8.27 8.47 7.17 6.98 6.89 6.99 7.24 7.57
Total Non-Interest Income		 35 36 36 36 36 33 35 34 34 35
Other Service Charges		 0.06 0.02 0.03 0.03 0.02 0.03 0.05 0.03 0.09 0.21
Other Non-Interest Income		 35 36 36 36 35 33 35 34 34 35
Total Non-Interest Expense		 25 26 26 26 26 25 26 26 25 29
Other Operating Expenses		 11 11 11 12 12 10 12 12 12 15
Depreciation Expense		 10 11 10 10 10 10 10 10 9.99 10
Amortization Expense		 4.29 4.51 4.40 4.34 4.10 4.04 3.97 3.87 3.65 3.45
Restructuring Charge		 0.11 0.11 0.04 0.00 0.00 - 0.00 0.00 0.00 0.16
Net Income / (Loss) Discontinued Operations		 6.75 - 0.49 13 2.29 - 0.00 -3.38 1.82 5.77
Preferred Stock Dividends Declared		 1.46 1.46 1.46 1.46 1.46 1.46 1.46 1.46 1.46 1.46
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.52 0.02 0.05 0.90 0.24 -0.07 0.07 -0.26 0.15 0.11
Basic Earnings per Share		 $0.12 $0.01 $0.01 $0.18 $0.05 ($0.01) $0.01 ($0.05) $0.03 $0.02
Weighted Average Basic Shares Outstanding		 65.52M 65.46M 65.53M 65.54M 65.57M 65.55M 65.57M 65.59M 65.74M 65.94M
Diluted Earnings per Share		 $0.12 $0.01 $0.01 $0.18 $0.05 ($0.01) $0.01 ($0.05) $0.03 $0.02
Weighted Average Diluted Shares Outstanding		 65.52M 65.46M 65.53M 65.54M 65.57M 65.55M 65.57M 65.59M 65.74M 65.94M
Weighted Average Basic & Diluted Shares Outstanding		 65.52M 65.53M 65.53M 65.56M 65.56M 65.57M 65.59M 65.59M 66.80M 66.87M

Annual Cash Flow Statements for Global Medical REIT

This table details how cash moves in and out of Global Medical REIT's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 1.70 -7.73 2.22
Net Cash From Operating Activities		 77 68 70
Net Cash From Continuing Operating Activities		 77 68 70
Net Income / (Loss) Continuing Operations		 20 22 6.69
Consolidated Net Income / (Loss)		 20 22 6.69
Depreciation Expense		 40 41 40
Amortization Expense		 20 20 18
Non-Cash Adjustments to Reconcile Net Income		 -1.58 -8.99 2.99
Changes in Operating Assets and Liabilities, net		 -1.74 -5.69 2.04
Net Cash From Investing Activities		 -137 68 -46
Net Cash From Continuing Investing Activities		 -137 68 -46
Purchase of Investment Securities		 -156 -11 -103
Sale and/or Maturity of Investments		 18 79 57
Other Investing Activities, net		 1.00 0.00 0.00
Net Cash From Financing Activities		 62 -144 -22
Net Cash From Continuing Financing Activities		 62 -144 -22
Net Change in Deposits		 -1.97 7.16 0.25
Issuance of Debt		 139 83 144
Issuance of Common Equity		 9.90 0.00 11
Repayment of Debt		 -20 -169 -111
Payment of Dividends		 -64 -65 -66
Cash Interest Paid		 22 30 27

Quarterly Cash Flow Statements for Global Medical REIT

This table details how cash moves in and out of Global Medical REIT's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -0.61 0.86 -0.47 -4.20 -2.17 -0.89 1.08 0.01 -0.03 1.15
Net Cash From Operating Activities		 18 18 16 18 17 18 14 19 16 21
Net Cash From Continuing Operating Activities		 18 18 16 18 17 18 14 19 16 21
Net Income / (Loss) Continuing Operations		 10 1.85 2.17 14 4.83 0.55 2.31 -1.95 3.39 2.94
Consolidated Net Income / (Loss)		 10 1.85 2.17 14 4.83 0.55 2.31 -1.95 3.39 2.94
Depreciation Expense		 10 11 10 10 10 10 10 10 9.99 10
Amortization Expense		 5.06 5.38 5.27 5.19 4.87 4.79 4.68 4.58 4.39 4.26
Non-Cash Adjustments to Reconcile Net Income		 -5.54 1.15 0.22 -11 -0.86 3.11 1.44 5.61 -0.61 -3.44
Changes in Operating Assets and Liabilities, net		 -1.36 -0.65 -2.38 -0.50 -2.27 -0.54 -4.25 0.57 -0.86 6.57
Net Cash From Investing Activities		 -33 -1.41 3.09 62 5.66 -3.11 -2.72 1.79 -25 -20
Net Cash From Continuing Investing Activities		 -33 -1.41 3.09 62 5.66 -3.11 -2.72 1.79 -25 -20
Purchase of Investment Securities		 -53 -1.89 -0.81 -2.53 -3.86 -4.11 -2.55 -5.21 -36 -59
Sale and/or Maturity of Investments		 18 0.17 4.05 64 9.53 1.00 -0.17 7.49 12 38
Other Investing Activities, net		 1.49 0.30 -0.15 0.15 - - 0.00 -0.50 -0.75 1.25
Net Cash From Financing Activities		 15 -16 -19 -84 -25 -16 -10 -21 9.16 0.15
Net Cash From Continuing Financing Activities		 15 -16 -19 -84 -25 -16 -10 -21 9.16 0.15
Net Change in Deposits		 -0.44 -0.57 -0.64 -0.26 -0.14 8.20 -0.06 0.31 -0.02 0.02
Issuance of Debt		 35 12 13 12 14 45 14 25 44 61
Repayment of Debt		 -3.53 -11 -15 -80 -22 -53 -8.03 -29 -30 -44
Payment of Dividends		 -16 -16 -16 -16 -16 -16 -16 -16 -16 -17
Cash Interest Paid		 6.21 6.37 8.14 8.15 7.00 6.86 6.41 6.18 6.94 7.05

Annual Balance Sheets for Global Medical REIT

This table presents Global Medical REIT's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 1,393 1,268 1,256
Cash and Due from Banks		 4.02 1.28 6.82
Restricted Cash		 10 5.45 2.13
Interest Bearing Deposits at Other Banks		 7.83 0.67 0.71
Trading Account Securities		 35 25 19
Loans and Leases, Net of Allowance		 0.00 0.00 0.00
Premises and Equipment, Net		 1,072 974 953
Deferred Acquisition Cost		 30 27 28
Goodwill		 5.90 5.90 5.90
Intangible Assets		 148 139 139
Other Assets		 81 89 102
Total Liabilities & Shareholders' Equity		 1,393 1,268 1,256
Total Liabilities		 744 662 701
Non-Interest Bearing Deposits		 5.46 3.69 3.32
Short-Term Debt		 636 585 632
Other Short-Term Payables		 30 29 33
Long-Term Debt		 58 26 14
Other Long-Term Liabilities		 15 18 18
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 649 606 556
Total Preferred & Common Equity		 633 584 534
Preferred Stock		 75 75 75
Total Common Equity		 558 509 459
Common Stock		 722 722 734
Retained Earnings		 -199 -239 -294
Accumulated Other Comprehensive Income / (Loss)		 35 25 19
Noncontrolling Interest		 16 22 22

Quarterly Balance Sheets for Global Medical REIT

This table presents Global Medical REIT's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 1,407 1,369 1,321 1,303 1,264 1,241 1,243
Cash and Due from Banks		 3.20 4.60 2.46 1.28 1.33 4.98 5.72
Restricted Cash		 10 9.38 7.33 6.33 6.47 2.84 2.07
Interest Bearing Deposits at Other Banks		 7.66 8.63 9.73 9.86 0.74 0.93 1.69
Trading Account Securities		 37 27 36 38 29 28 15
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 1,087 1,053 1,007 988 960 941 948
Deferred Acquisition Cost		 29 30 26 27 28 28 28
Goodwill		 5.90 5.90 5.90 5.90 5.90 5.90 5.90
Intangible Assets		 148 148 140 139 139 136 138
Other Assets		 78 81 86 87 93 93 98
Total Liabilities & Shareholders' Equity		 1,407 1,369 1,321 1,303 1,264 1,241 1,243
Total Liabilities		 742 741 679 669 666 663 678
Non-Interest Bearing Deposits		 5.40 4.69 4.21 3.91 4.38 3.97 3.22
Short-Term Debt		 635 635 568 561 592 599 614
Other Short-Term Payables		 29 28 32 29 27 28 30
Long-Term Debt		 58 57 57 57 26 15 14
Other Long-Term Liabilities		 15 15 19 18 18 17 16
Total Equity & Noncontrolling Interests		 665 628 641 634 597 578 565
Total Preferred & Common Equity		 649 613 620 611 575 556 543
Preferred Stock		 75 75 75 75 75 75 75
Total Common Equity		 574 538 545 536 500 481 468
Common Stock		 722 722 722 722 723 723 734
Retained Earnings		 -185 -212 -214 -224 -252 -269 -281
Accumulated Other Comprehensive Income / (Loss)		 37 27 36 38 29 28 15
Noncontrolling Interest		 16 16 22 22 22 22 22

Annual Metrics And Ratios for Global Medical REIT

This table displays calculated financial ratios and metrics derived from Global Medical REIT's official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 16.43% -1.69% -0.06%
EBITDA Growth		 9.83% -6.40% -8.62%
EBIT Growth		 -23.33% -46.82% -40.32%
NOPAT Growth		 -23.33% -46.82% -40.32%
Net Income Growth		 9.02% 8.69% -69.21%
EPS Growth		 5.26% 15.00% -95.65%
Operating Cash Flow Growth		 10.98% -10.58% 2.35%
Free Cash Flow Firm Growth		 17.87% 218.02% -85.58%
Invested Capital Growth		 10.36% -9.39% -1.23%
Revenue Q/Q Growth		 7.41% -2.01% 1.48%
EBITDA Q/Q Growth		 7.45% -2.00% -4.68%
EBIT Q/Q Growth		 22.69% -5.73% -37.57%
NOPAT Q/Q Growth		 -16.26% -5.73% -37.57%
Net Income Q/Q Growth		 -15.40% -5.63% 55.48%
EPS Q/Q Growth		 -20.00% -8.00% 150.00%
Operating Cash Flow Q/Q Growth		 1.36% -0.27% 3.54%
Free Cash Flow Firm Q/Q Growth		 28.01% 17.22% -70.23%
Invested Capital Q/Q Growth		 -1.05% -2.73% 0.72%
Profitability Metrics		 - - -
EBITDA Margin		 65.24% 62.12% 56.80%
EBIT Margin		 11.82% 6.39% 3.82%
Profit (Net Income) Margin		 17.85% 19.73% 6.08%
Tax Burden Percent		 150.99% 308.63% 159.22%
Interest Burden Percent		 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 1.03% 0.55% 0.35%
ROIC Less NNEP Spread (ROIC-NNEP)		 2.09% 2.80% 0.74%
Return on Net Nonoperating Assets (RNNOA)		 2.07% 2.91% 0.80%
Return on Equity (ROE)		 3.11% 3.46% 1.15%
Cash Return on Invested Capital (CROIC)		 -8.82% 10.40% 1.59%
Operating Return on Assets (OROA)		 1.00% 0.53% 0.33%
Return on Assets (ROA)		 1.51% 1.63% 0.53%
Return on Common Equity (ROCE)		 2.67% 2.94% 0.96%
Return on Equity Simple (ROE_SIMPLE)		 3.16% 3.72% 1.25%
Net Operating Profit after Tax (NOPAT)		 13 7.04 4.20
NOPAT Margin		 11.82% 6.39% 3.82%
Net Nonoperating Expense Percent (NNEP)		 -1.06% -2.25% -0.40%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 88.18% 93.61% 96.18%
Earnings before Interest and Taxes (EBIT)		 13 7.04 4.20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 73 68 63
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.93 1.30 1.12
Price to Tangible Book Value (P/TBV)		 1.28 1.82 1.64
Price to Revenue (P/Rev)		 4.62 6.01 4.68
Price to Earnings (P/E)		 38.84 44.77 635.91
Dividend Yield		 10.64% 8.32% 10.88%
Earnings Yield		 2.57% 2.23% 0.16%
Enterprise Value to Invested Capital (EV/IC)		 0.95 1.12 1.04
Enterprise Value to Revenue (EV/Rev)		 11.43 12.38 11.34
Enterprise Value to EBITDA (EV/EBITDA)		 17.51 19.92 19.97
Enterprise Value to EBIT (EV/EBIT)		 96.67 193.58 297.16
Enterprise Value to NOPAT (EV/NOPAT)		 96.67 193.58 297.16
Enterprise Value to Operating Cash Flow (EV/OCF)		 16.73 19.92 17.83
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 10.24 65.04
Leverage & Solvency		 - - -
Debt to Equity		 1.07 1.01 1.16
Long-Term Debt to Equity		 0.09 0.04 0.03
Financial Leverage		 0.99 1.04 1.08
Leverage Ratio		 2.06 2.12 2.17
Compound Leverage Factor		 2.06 2.12 2.17
Debt to Total Capital		 51.68% 50.22% 53.75%
Short-Term Debt to Total Capital		 47.38% 48.09% 52.55%
Long-Term Debt to Total Capital		 4.29% 2.13% 1.20%
Preferred Equity to Total Capital		 5.58% 6.16% 6.24%
Noncontrolling Interests to Total Capital		 1.20% 1.83% 1.81%
Common Equity to Total Capital		 41.54% 41.79% 38.20%
Debt to EBITDA		 9.49 8.93 10.33
Net Debt to EBITDA		 9.19 8.82 10.18
Long-Term Debt to EBITDA		 0.79 0.38 0.23
Debt to NOPAT		 52.41 86.80 153.73
Net Debt to NOPAT		 50.73 85.75 151.43
Long-Term Debt to NOPAT		 4.35 3.68 3.43
Noncontrolling Interest Sharing Ratio		 14.05% 15.00% 16.69%
Liquidity Ratios		 - - -
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -113 133 19
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -4.47 4.31 0.67
Operating Cash Flow to Interest Expense		 3.03 2.22 2.44
Operating Cash Flow Less CapEx to Interest Expense		 3.03 2.22 2.44
Efficiency Ratios		 - - -
Asset Turnover		 0.08 0.08 0.09
Fixed Asset Turnover		 0.11 0.11 0.11
Capital & Investment Metrics		 - - -
Invested Capital		 1,343 1,217 1,202
Invested Capital Turnover		 0.09 0.09 0.09
Increase / (Decrease) in Invested Capital		 126 -126 -15
Enterprise Value (EV)		 1,280 1,363 1,249
Market Capitalization		 517 662 516
Book Value per Share		 $8.52 $7.76 $6.87
Tangible Book Value per Share		 $6.17 $5.55 $4.71
Total Capital		 1,343 1,217 1,202
Total Debt		 694 611 646
Total Long-Term Debt		 58 26 14
Net Debt		 672 604 636
Capital Expenditures (CapEx)		 0.00 0.00 0.00
Net Nonoperating Expense (NNE)		 -6.75 -15 -2.49
Net Nonoperating Obligations (NNO)		 694 611 646
Total Depreciation and Amortization (D&A)		 60 61 58
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.20 $0.23 $0.01
Adjusted Weighted Average Basic Shares Outstanding		 65.46M 65.55M 65.94M
Adjusted Diluted Earnings per Share		 $0.20 $0.23 $0.01
Adjusted Weighted Average Diluted Shares Outstanding		 65.46M 65.55M 65.94M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 65.53M 65.57M 66.87M
Normalized Net Operating Profit after Tax (NOPAT)		 9.52 4.96 3.05
Normalized NOPAT Margin		 8.49% 4.50% 2.77%
Pre Tax Income Margin		 11.82% 6.39% 3.82%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.52 0.23 0.15
NOPAT to Interest Expense		 0.52 0.23 0.15
EBIT Less CapEx to Interest Expense		 0.52 0.23 0.15
NOPAT Less CapEx to Interest Expense		 0.52 0.23 0.15
Payout Ratios		 - - -
Dividend Payout Ratio		 321.27% 298.37% 981.62%
Augmented Payout Ratio		 321.27% 298.37% 981.62%

Quarterly Metrics And Ratios for Global Medical REIT

This table displays calculated financial ratios and metrics derived from Global Medical REIT's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 13.08% 37.66% 3.27% -1.46% -0.37% -8.01% 0.96% -2.27% -4.62% 6.19%
EBITDA Growth		 2.57% 39.75% -3.91% -8.70% -5.15% -7.83% -1.97% -5.38% -8.93% -18.72%
EBIT Growth		 -38.97% 406.81% -60.62% -63.72% -22.34% -23.17% 37.09% 2.88% -38.36% -178.22%
NOPAT Growth		 -38.97% -58.19% -60.62% -63.72% -22.34% -23.17% 37.09% 2.88% -38.36% -154.76%
Net Income Growth		 86.83% -66.34% -49.30% 269.77% -51.81% -70.17% 6.49% -113.77% -29.84% 433.39%
EPS Growth		 100.00% -83.33% -75.00% 500.00% -58.33% -200.00% 0.00% -127.78% -40.00% 300.00%
Operating Cash Flow Growth		 -1.58% 5.93% -4.05% -23.87% -9.00% -1.00% -9.37% 5.87% -2.18% 13.23%
Free Cash Flow Firm Growth		 11.53% 17.31% 49.54% 127.14% 164.20% 202.67% 237.84% 73.77% -45.40% -88.85%
Invested Capital Growth		 14.57% 10.36% 6.46% -3.23% -7.82% -9.39% -8.01% -5.88% -4.62% -1.23%
Revenue Q/Q Growth		 0.52% -0.71% -1.00% -0.27% 1.63% -8.33% 8.67% -3.47% -0.81% 2.06%
EBITDA Q/Q Growth		 -1.16% -3.52% -2.04% -2.26% 2.68% -6.24% 4.18% -5.65% -1.17% -16.32%
EBIT Q/Q Growth		 -14.55% -43.62% -8.61% -17.59% 82.89% -44.22% 63.07% -38.16% 9.57% -170.79%
NOPAT Q/Q Growth		 -14.55% -43.62% -8.61% -17.59% 82.89% -44.22% 63.07% -38.16% 9.57% -149.55%
Net Income Q/Q Growth		 161.58% -81.58% 17.65% 552.42% -65.91% -88.60% 319.96% -184.36% 273.72% -13.33%
EPS Q/Q Growth		 300.00% -91.67% 0.00% 1,700.00% -72.22% -120.00% 200.00% -600.00% 160.00% -33.33%
Operating Cash Flow Q/Q Growth		 -22.01% -0.03% -13.86% 13.36% -6.78% 8.75% -21.14% 32.43% -13.87% 25.89%
Free Cash Flow Firm Q/Q Growth		 -5.20% 26.61% 36.88% 155.69% 148.87% 17.36% -15.26% -29.79% -21.81% -76.03%
Invested Capital Q/Q Growth		 3.71% -1.05% -1.68% -4.10% -1.20% -2.73% -0.18% -1.88% 0.12% 0.72%
Profitability Metrics		 - - - - - - - - - -
EBITDA Margin		 64.91% 63.07% 62.40% 61.16% 61.79% 63.20% 60.59% 59.22% 59.00% 48.37%
EBIT Margin		 11.52% 6.54% 6.04% 4.99% 8.98% 5.46% 8.20% 5.25% 5.80% -4.02%
Profit (Net Income) Margin		 35.26% 6.54% 7.77% 50.84% 17.06% 2.12% 8.20% -7.16% 12.55% 10.65%
Tax Burden Percent		 306.14% 100.00% 128.73% 1,019.19% 189.98% 38.83% 100.00% -136.41% 216.26% -264.77%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.95% 0.57% 0.53% 0.44% 0.77% 0.47% 0.71% 0.47% 0.51% -0.26%
ROIC Less NNEP Spread (ROIC-NNEP)		 2.03% 0.57% 0.61% 2.43% 1.12% 0.34% 0.71% -0.08% 0.81% 0.33%
Return on Net Nonoperating Assets (RNNOA)		 1.95% 0.57% 0.61% 2.42% 1.13% 0.35% 0.76% -0.08% 0.84% 0.36%
Return on Equity (ROE)		 2.90% 1.14% 1.14% 2.85% 1.91% 0.82% 1.48% 0.39% 1.35% 0.11%
Cash Return on Invested Capital (CROIC)		 -12.33% -8.82% -5.42% 3.92% 8.71% 10.40% 8.95% 6.68% 5.28% 1.59%
Operating Return on Assets (OROA)		 0.91% 0.55% 0.51% 0.42% 0.75% 0.45% 0.69% 0.45% 0.49% -0.35%
Return on Assets (ROA)		 2.78% 0.55% 0.66% 4.27% 1.42% 0.18% 0.69% -0.61% 1.07% 0.93%
Return on Common Equity (ROCE)		 2.50% 0.98% 0.98% 2.44% 1.63% 0.70% 1.25% 0.33% 1.14% 0.09%
Return on Equity Simple (ROE_SIMPLE)		 3.64% 0.00% 2.92% 4.56% 3.77% 0.00% 3.80% 1.03% 0.79% 0.00%
Net Operating Profit after Tax (NOPAT)		 3.28 1.85 1.69 1.39 2.54 1.42 2.31 1.43 1.57 -0.78
NOPAT Margin		 11.52% 6.54% 6.04% 4.99% 8.98% 5.46% 8.20% 5.25% 5.80% -2.82%
Net Nonoperating Expense Percent (NNEP)		 -1.08% 0.00% -0.08% -1.99% -0.35% 0.13% 0.00% 0.55% -0.29% -0.59%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 88.48% 93.46% 93.96% 95.01% 91.02% 94.54% 91.80% 94.75% 94.20% 104.02%
Earnings before Interest and Taxes (EBIT)		 3.28 1.85 1.69 1.39 2.54 1.42 2.31 1.43 1.57 -1.11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 18 18 17 17 18 16 17 16 16 13
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.83 0.93 0.99 1.01 1.01 1.30 1.12 1.24 1.39 1.12
Price to Tangible Book Value (P/TBV)		 1.14 1.28 1.39 1.37 1.38 1.82 1.58 1.76 2.01 1.64
Price to Revenue (P/Rev)		 4.57 4.62 4.73 4.87 4.80 6.01 5.08 5.42 5.99 4.68
Price to Earnings (P/E)		 28.46 38.84 47.19 26.21 33.73 44.77 37.61 0.00 0.00 635.91
Dividend Yield		 11.47% 10.64% 10.29% 10.04% 10.21% 8.32% 9.82% 9.25% 8.48% 10.88%
Earnings Yield		 3.51% 2.57% 2.12% 3.82% 2.96% 2.23% 2.66% 0.00% 0.00% 0.16%
Enterprise Value to Invested Capital (EV/IC)		 0.91 0.95 0.98 0.99 0.99 1.12 1.04 1.09 1.14 1.04
Enterprise Value to Revenue (EV/Rev)		 11.88 11.43 11.47 11.11 11.00 12.38 11.47 11.82 12.60 11.34
Enterprise Value to EBITDA (EV/EBITDA)		 18.21 17.51 17.89 17.67 17.72 19.92 18.61 19.32 20.83 19.97
Enterprise Value to EBIT (EV/EBIT)		 114.82 96.67 121.65 152.47 165.58 193.58 165.24 168.31 202.97 297.16
Enterprise Value to NOPAT (EV/NOPAT)		 78.37 96.67 121.65 152.47 165.58 193.58 165.24 168.31 202.97 297.16
Enterprise Value to Operating Cash Flow (EV/OCF)		 16.41 16.73 17.07 17.80 18.02 19.92 18.92 19.08 20.20 17.83
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 24.77 10.89 10.24 11.17 15.79 21.18 65.04
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 1.04 1.07 1.10 0.97 0.97 1.01 1.03 1.06 1.11 1.16
Long-Term Debt to Equity		 0.09 0.09 0.09 0.09 0.09 0.04 0.04 0.03 0.03 0.03
Financial Leverage		 0.96 0.99 1.00 1.00 1.01 1.04 1.07 1.02 1.04 1.08
Leverage Ratio		 2.05 2.06 2.07 2.08 2.09 2.12 2.15 2.10 2.12 2.17
Compound Leverage Factor		 2.05 2.06 2.07 2.08 2.09 2.12 2.15 2.10 2.12 2.17
Debt to Total Capital		 51.04% 51.68% 52.41% 49.36% 49.36% 50.22% 50.85% 51.48% 52.69% 53.75%
Short-Term Debt to Total Capital		 46.77% 47.38% 48.07% 44.85% 44.82% 48.09% 48.74% 50.25% 51.48% 52.55%
Long-Term Debt to Total Capital		 4.27% 4.29% 4.34% 4.51% 4.54% 2.13% 2.11% 1.23% 1.21% 1.20%
Preferred Equity to Total Capital		 5.52% 5.58% 5.68% 5.92% 5.99% 6.16% 6.17% 6.29% 6.28% 6.24%
Noncontrolling Interests to Total Capital		 1.17% 1.20% 1.19% 1.72% 1.77% 1.83% 1.82% 1.84% 1.85% 1.81%
Common Equity to Total Capital		 42.27% 41.54% 40.72% 43.00% 42.88% 41.79% 41.16% 40.39% 39.18% 38.20%
Debt to EBITDA		 10.18 9.49 9.56 8.83 8.85 8.93 9.07 9.14 9.59 10.33
Net Debt to EBITDA		 9.87 9.19 9.25 8.56 8.60 8.82 8.95 9.01 9.44 10.18
Long-Term Debt to EBITDA		 0.85 0.79 0.79 0.81 0.81 0.38 0.38 0.22 0.22 0.23
Debt to NOPAT		 43.81 52.41 65.02 76.21 82.68 86.80 80.56 79.61 93.42 153.73
Net Debt to NOPAT		 42.47 50.73 62.90 73.84 80.34 85.75 79.45 78.48 92.01 151.43
Long-Term Debt to NOPAT		 3.66 4.35 5.39 6.96 7.61 3.68 3.35 1.90 2.15 3.43
Noncontrolling Interest Sharing Ratio		 13.93% 14.05% 14.07% 14.48% 14.48% 15.00% 15.32% 15.88% 16.20% 16.69%
Liquidity Ratios		 - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -169 -124 -78 44 109 128 108 76 59 14
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -24.31 -15.41 -9.48 5.16 15.16 18.26 15.69 10.85 8.20 1.88
Operating Cash Flow to Interest Expense		 2.63 2.27 1.91 2.11 2.32 2.60 2.07 2.71 2.25 2.71
Operating Cash Flow Less CapEx to Interest Expense		 2.63 2.27 1.91 2.11 2.32 2.60 2.07 2.71 2.25 2.71
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.08 0.08 0.09 0.08 0.08 0.08 0.08 0.09 0.09 0.09
Fixed Asset Turnover		 0.10 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 1,357 1,343 1,321 1,267 1,251 1,217 1,215 1,192 1,193 1,202
Invested Capital Turnover		 0.08 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09
Increase / (Decrease) in Invested Capital		 173 126 80 -42 -106 -126 -106 -74 -58 -15
Enterprise Value (EV)		 1,239 1,280 1,295 1,251 1,237 1,363 1,267 1,297 1,366 1,249
Market Capitalization		 477 517 535 548 540 662 561 596 650 516
Book Value per Share		 $8.76 $8.52 $8.21 $8.31 $8.18 $7.76 $7.63 $7.34 $7.13 $6.87
Tangible Book Value per Share		 $6.41 $6.17 $5.85 $6.09 $5.98 $5.55 $5.42 $5.17 $4.94 $4.71
Total Capital		 1,357 1,343 1,321 1,267 1,251 1,217 1,215 1,192 1,193 1,202
Total Debt		 693 694 692 625 618 611 618 614 629 646
Total Long-Term Debt		 58 58 57 57 57 26 26 15 14 14
Net Debt		 672 672 670 606 600 604 609 605 619 636
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Nonoperating Expense (NNE)		 -6.75 0.00 -0.49 -13 -2.29 0.87 0.00 3.38 -1.82 -3.72
Net Nonoperating Obligations (NNO)		 693 694 692 625 618 611 618 614 629 646
Total Depreciation and Amortization (D&A)		 15 16 16 16 15 15 15 15 14 14
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.12 $0.01 $0.01 $0.18 $0.05 ($0.01) $0.01 ($0.05) $0.03 $0.02
Adjusted Weighted Average Basic Shares Outstanding		 65.52M 65.46M 65.53M 65.54M 65.57M 65.55M 65.57M 65.59M 65.74M 65.94M
Adjusted Diluted Earnings per Share		 $0.12 $0.01 $0.01 $0.18 $0.05 ($0.01) $0.01 ($0.05) $0.03 $0.02
Adjusted Weighted Average Diluted Shares Outstanding		 65.52M 65.46M 65.53M 65.54M 65.57M 65.55M 65.57M 65.59M 65.74M 65.94M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 65.52M 65.53M 65.53M 65.56M 65.56M 65.57M 65.59M 65.59M 66.80M 66.87M
Normalized Net Operating Profit after Tax (NOPAT)		 2.37 1.37 1.21 0.98 1.78 0.99 1.62 1.00 1.10 -0.67
Normalized NOPAT Margin		 8.34% 4.86% 4.33% 3.50% 6.28% 3.82% 5.74% 3.68% 4.06% -2.42%
Pre Tax Income Margin		 11.52% 6.54% 6.04% 4.99% 8.98% 5.46% 8.20% 5.25% 5.80% -4.02%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.47 0.23 0.20 0.16 0.35 0.20 0.34 0.20 0.22 -0.15
NOPAT to Interest Expense		 0.47 0.23 0.20 0.16 0.35 0.20 0.34 0.20 0.22 -0.10
EBIT Less CapEx to Interest Expense		 0.47 0.23 0.20 0.16 0.35 0.20 0.34 0.20 0.22 -0.15
NOPAT Less CapEx to Interest Expense		 0.47 0.23 0.20 0.16 0.35 0.20 0.34 0.20 0.22 -0.10
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 268.92% 321.27% 360.20% 228.49% 280.81% 298.37% 297.57% 1,136.55% 1,519.49% 981.62%
Augmented Payout Ratio		 268.92% 321.27% 360.20% 228.49% 280.81% 298.37% 297.57% 1,136.55% 1,519.49% 981.62%

Financials Breakdown Chart

Key Financial Trends

Global Medical REIT (NYSE: GMRE) showed a mixed but improving operating picture in 2024, with stronger quarterly earnings and operating cash flow than earlier in the year, but still carrying a heavy debt load and consistently high interest costs. The company also continues to rely on large non-interest income items, which makes results less predictable for retail investors.

  • Q4 2024 operating cash flow was strong at $20.5 million, up from $16.3 million in Q3 2024 and $18.9 million in Q2 2024.
  • Quarterly profitability improved in Q4 2024, with net income of $2.9 million versus $3.4 million in Q3, but importantly it rebounded from a $2.0 million loss in Q2.
  • Core continuing operations returned to positive territory in Q4 2024, with pre-tax income of $1.1 million compared with $1.6 million in Q3 and $1.4 million in Q2.
  • The company generated positive net change in cash and equivalents in Q4 2024 of $1.15 million, suggesting liquidity was stable at the end of the year.
  • Compared with 2023, 2024 showed better consistency in common-share profitability, with Q4 2024 common shareholder income of $1.37 million versus a $0.84 million loss in Q4 2023.
  • Total revenue in Q4 2024 was $27.6 million, only modestly above the $27.0 million to $27.3 million range seen in the prior three quarters, pointing to relatively stable top-line performance.
  • Non-interest income remains the main driver of revenue, at $35.2 million in Q4 2024, which is larger than total revenue because interest expense is reported separately and remains significant.
  • Assets were broadly flat year over year, with total assets at $1.243 billion in Q3 2024 versus $1.303 billion in Q3 2023 and $1.369 billion in Q1 2023, suggesting a gradually smaller balance sheet.
  • Debt levels remain elevated. Q3 2024 showed $614.4 million of short-term debt and $14.5 million of long-term debt, for a highly leveraged capital structure.
  • The dividend appears to remain a key cash use, with $16.6 million paid in Q4 2024 and roughly $16.3 million to $16.4 million paid in each of the prior quarters shown.
  • Interest expense remains a major burden. Q4 2024 total interest expense was $7.6 million, up from $7.2 million in Q3 2024 and $6.9 million in Q1 2024.
  • Cash interest paid was also high at $7.0 million in Q4 2024, indicating that debt service continues to pressure cash generation.
  • Investing cash flow was negative in Q4 2024 at -$19.5 million, reflecting continued reinvestment activity and reducing free cash available for shareholders.
  • The balance sheet shows retained earnings remained deeply negative at -$281.1 million in Q3 2024, a sign of long-term cumulative losses.
  • Quarterly earnings have been volatile over the past year, including a $2.0 million loss in Q2 2024 and a $0.8 million loss attributable to common shareholders in Q4 2023.

Bottom line: GMRE appears to have stabilized in 2024, with improving quarterly earnings and solid operating cash flow. However, the company still faces meaningful risks from leverage, recurring interest expense, and heavy dividend commitments. For investors, the near-term story looks more like stabilization than a full turnaround.

06/06/26 07:26 PM ETAI Generated. May Contain Errors.

Global Medical REIT Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Global Medical REIT's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

Global Medical REIT's net income appears to be on a downward trend, with a most recent value of $6.69 million in 2024, falling from $20.00 million in 2022. The previous period was $21.73 million in 2023. Find out what analysts predict for Global Medical REIT in the coming months.

Over the last 2 years, Global Medical REIT's total revenue changed from $112.05 million in 2022 to $110.09 million in 2024, a change of -1.8%.

Global Medical REIT's total liabilities were at $700.57 million at the end of 2024, a 5.8% increase from 2023, and a 5.9% decrease since 2022.

In the past 2 years, Global Medical REIT's cash and equivalents has ranged from $1.28 million in 2023 to $6.82 million in 2024, and is currently $6.82 million as of their latest financial filing in 2024.

Over the last 2 years, Global Medical REIT's book value per share changed from 8.52 in 2022 to 6.87 in 2024, a change of -19.3%.


Related Companies

Financial statements for NYSE:XRN last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
BUY THIS: Claim a backdoor stake in SpaceX before June 12
Marc Chaikin, the Wall Street veteran who spotted Nvidia before a 45,000% run, says there's a simple trade ava...
Chaikin Analytics | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
June 12 is 9 days away. Move now.
SpaceX is set to price on June 12 in what could be the largest IPO in history at a $1.75 trillion valuation. B...
Behind the Markets | Sponsoredtc pixel